ProMIS Neurosciences, Inc. (PMN)

NASDAQ: PMN · IEX Real-Time Price · USD
2.010
-0.090 (-4.29%)
Feb 26, 2024, 10:13 AM EST - Market open

Company Description

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada.

The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.

Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils.

The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015.

ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

ProMIS Neurosciences, Inc.
ProMIS Neurosciences logo
Country Canada
Founded 2004
Industry Biotechnology
Sector Healthcare
Employees 6
CEO Neil K. Warma M.B.A.

Contact Details

Address:
Suite 200, 1920 Yonge Street
Toronto, A6 M4S 3E2
Ontario, Canada
Phone 416-847-6898
Website promisneurosciences.com

Stock Details

Ticker Symbol PMN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001374339
CUSIP Number 74346M406
ISIN Number CA74346M4065
SIC Code 2834

Key Executives

Name Position
Eugene Williams Co-Founder and Chairman
Neil K. Warma M.B.A. President, Interim Chief Executive Officer, Principal Executive Officer and Director
Dr. Neil R. Cashman M.D. Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer and Director
Gavin T. Malenfant Chief Operating Officer
Daniel E. Geffken M.B.A. Chief Financial Officer
Dr. Johanne Kaplan Ph.D. Chief Development Officer
Dr. Ernest D. Bush Ph.D. Head of Pharmacology/Toxicology and Senior Consultant
Dr. David Wishart Ph.D. Chief Physics Officer
Dennis Chen Ph.D. Head of Manufacturing and Senior Consultant
Dr. Larry Douglas Altstiel M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Feb 5, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 5, 2024 8-K Current Report
Jan 5, 2024 424B5 Filing
Jan 3, 2024 8-K Current Report
Jan 2, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Dec 27, 2023 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Dec 8, 2023 8-K Current Report
Nov 20, 2023 8-K Current Report
Nov 14, 2023 8-K Current Report
Nov 14, 2023 10-Q Quarterly Report